Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a global consumer-health company listed on the LSE and NYSE, filed this Form 6-K for April 2024. The exhibit is dated 2 April 2024 and reports total voting rights and share capital as of 31 March 2024.
Haleon’s principal product categories are oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements. Its brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.
Share capital and other key metrics
- Total issued ordinary shares with voting rights: 9,132,301,104.
- Nominal value per ordinary share: £0.01.
- Ordinary shares held in treasury: None.
- The reported share count may be used as the denominator for shareholder notifications under the FCA Disclosure Guidance and Transparency Rules.
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-performance metrics.
Material changes versus the prior comparable period
The filing does not provide a prior-period comparison or identify changes in issued share capital or voting rights relative to the preceding reporting period.
Guidance, outlook, risks and unusual items
The filing contains no management guidance, financial outlook, risk discussion, contingencies, or unusual items. It is limited to a total voting rights and capital disclosure.
Facts investors should verify
- Verify the applicable voting-rights denominator of 9,132,301,104 shares for FCA disclosure calculations.
- Confirm that no ordinary shares were held in treasury as of 31 March 2024.
- Consult Haleon’s other filings for financial results, leverage, liquidity, guidance, and operating trends, which are not covered by this Form 6-K.